Study Enrollment

Your details will not be published or shared.

Clinical Trial

Amifampridine for the Treatment of Transient Vocal Weakness after OnabotulinumtoxinA Injection for Spasmodic Dysphonia

In this study, we will be looking at how well the drug amifampridine, also known as Firdapse, works to relieve the temporary symptoms of voice weakness and breathiness that can occur after a patient with adductor spasmodic dysphonia receive a Botox injection to treat their condition. Participation in the full study will last about 2 months.

Eligibility Criteria

  • Inclusion Criteria: You are 18 years old or older You receive onabotulinumtoxinA treatment for Adductor Spasmodic Dysphonia Your voice gets breathy or weak within 5 days following your onabotulinumtoxinA injection Exclusion Criteria: Known history of seizures Known allergy to the drug or its components.

Contact Information

    Brandy Quarles

    (706) 721-2681